Benchmark Holdings PLC, listed on AIM
Benchmark (AIM: BMK), an established international animal health, technical publishing and sustainability science business, is pleased to announce that its shares will today be admitted to trading on AIM.
In an oversubscribed fundraising led by Cenkos Securities and supported by Equity Development, Benchmark has successfully raised £27.5 million before expenses through the sale of new ordinary shares at a price of 64 pence per share to a diverse range of investors. In addition, existing shareholders have sold shares worth £17.6 million. Total gross proceeds from the placing amounted to £45.1 million, making this the largest fundraising in the healthcare sector this year on AIM. At admission, the Company will have a total of 136,416,750 ordinary shares in issue.
The proceeds of the fundraising will be used by Benchmark to invest in high quality scientific research and development, to enhance its business development team, to expand its core businesses and enter into new segments which fit synergistically with its existing businesses. The proceeds will also be used to fund the expansion of Benchmark’s manufacturing base, as well as selective acquisitions.
We are really pleased that Benchmark has been so well received. The quality and breadth of our new shareholder base is evidence to the confidence people have in our Company
“Our goal has always been to become a world leading specialist in the development of a sustainable food chain with a particular focus on the development of aquaculture health. The AIM market will provide Benchmark with access to capital and tradable equity, enabling us to pursue a strong pipeline of potential new products and technologies and continue to build the group by acquisition. The team and I are looking forward to this exciting new chapter in Benchmark’s development.”